- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00786019
Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes (InsITE)
Influence Of Endothelial Function On Central and Peripheral Causes Of Exercise Impairment In Type 2 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators have found that persons with type 2 diabetes have an impaired ability to perform exercise even without clinically apparent complications. The reasons for this marked abnormality are unknown but are important as the decreased ability to exercise could contribute to the decreased expenditure of physical activity frequently observed in this population and may potentially constitute an early marker of cardiovascular disease.
The investigators wish to evaluate the effects of impaired blood flow regulation on exercise capacity and whether the effects are more important in the heart or in the skeletal muscle tissue during exercise. In addition, the investigators are determining whether correcting these abnormalities by two methods of improving blood flow regulation (acutely infusing Vitamin C or three months of chronic exercise training) leads to improved blood flow regulation, improved heart and skeletal muscle tissue function and hence to better exercise capacity in person with type 2 diabetes. This information will provide a more mechanistic understanding of causes of abnormal exercise responses observed in person with type 2 diabetes as well as whether and to what degree responses are modifiable. Interventions that reverse the exercise defect may facilitate patient adherence to prescribed physical activity programs and potentially decrease cardiovascular mortality in this large segment of the population.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Denver
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women with uncomplicated Type 2 Diabetes
- Healthy men and women without Type 2 Diabetes
- Patients with Type 2 Diabetes may be taking metformin or sulfonylurea drugs to treat diabetes
- Persons with history of hypercholesteremia if controlled with statins and/or diet
- Patients who are moderately overweight (BMI 25-37.5)
- Must be sedentary (defined as regular exercise < 2 times a week at a low to moderate level).
- Patients with Hemoglobin A1c (HBA1C) <8%
- Patients between the ages of 30 to 55 years
- Premenopausal women.
- Former smokers who have quit smoking for at least one year
- Absence of comorbid conditions
- Mild neuropathy is O.K. as long as it will not hamper exercise performance.
- Resting systolic blood pressure (SBP) < 140, Resting diastolic blood pressure (DBP) < 90
- Total Cholesterol < 205 Triglycerides < 250 low density lipoprotein (LDL) < 130
- Control subjects with a normal A1C and fasting glucose
Exclusion Criteria:
- People with T2DM taking oral medications, other than metformin or sulfonylurea drugs to control their diabetes.
- Persons treated with insulin will be excluded
- People who are currently smoking or have not quit for at least one year
- Controls who have immediate family history of T2DM
- Peri-menopausal or post-menopausal women.
- Peripheral neuropathy
- Total cholesterol > 205
- Regional wall motion abnormalities
- LV wall thickness ≥1.1 cm
- Decreased contractility (fractional shortening <30%)
- Ischemic heart disease (abnormal resting or exercise ECG)
- Presence of angina that would limit exercise performance
- Pulmonary problems that would limit exercise performance
- Systolic blood pressure >140 mmHg at rest or >250 mmHg with exercise or diastolic pressure >90 mmHg at rest or >105 mmHg with exercise
- Persons with autonomic insufficiency, assessed by measuring variation in RR intervals with cycled breathing and by presence of a >20 mm fall in upright blood pressure without a change in heart rate
- Proteinuria (urine protein >200 mg/dl) or a creatinine > 2 mg/dl
- Renal disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ascorbic acid
All study subjects have ascorbic acid infusion during one exercise visit as well as a three month exercise training intervention.
|
Three month exercise program located at the Anschutz Medical Campus at I-225 and Colfax.
The program runs three times per week for about an hour each session.
Gym is open Monday - Saturday during specific hours (morning, noon, evening).
Other Names:
During one exercise study visit, 0.06 grams of Vitamin C per kilogram fat-free mass per 100 milliliters (mL) of normal saline administered; Subjects will receive a bolus of 100mL Vitamin C solution given at 5ml/minute over 20 minutes followed by a "drip-infusion" given at 1.7ml/minute.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change in Circumferential Strain Before and After Exercise at Baseline, After Vitamin C Infusion, and After Exercise Training
Time Frame: 7 months; Measures are made at rest and after exercise for baseline, at rest and after infusion for Vitamin C administration, and at rest and after exercise following the exercise training
|
Characterize the purported cardiac dysfunction during exercise in people with type 2 diabetes (T2D).
In a normal patient when measuring circumferential strain, results are negative with downward tracing (as strain is a relative change in length).
Circumferential strain is a measurement of ventricular circumference within the heart vessels, measured via echocardiography.
|
7 months; Measures are made at rest and after exercise for baseline, at rest and after infusion for Vitamin C administration, and at rest and after exercise following the exercise training
|
Ejection Fraction: Percentage of Blood Leaving the Heart Before and After Exercise at Baseline, After a Vitamin C Infusion, and After Exercise Training
Time Frame: 7 months; Measures are made at rest for baseline, at rest for Vitamin C administration, and at rest following the exercise training
|
Evaluate potential changes in cardiac function by echocardiography following 2 interventions: Three months of exercise training and acute vitamin C administration.
Ejection fraction (EF) is a measurement of the percentage of blood leaving your heart each time it contracts, typically measure by echocardiography.
Numbers listed are absolute EF values.
|
7 months; Measures are made at rest for baseline, at rest for Vitamin C administration, and at rest following the exercise training
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Judith G Regensteiner, PhD, University of Colorado, Denver
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 07-1152
- UL1TR000154 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Exercise program
-
Azienda Sanitaria Locale CN1 CuneoNot yet recruiting
-
University of MiamiRecruiting
-
Riphah International UniversityCompletedSports Physical Therapy | Sports InjuryPakistan
-
Marmara UniversityCompletedCervical Disc HerniationTurkey
-
Marius HenriksenCompletedPatellofemoral Pain SyndromeDenmark
-
University of ÉvoraSão João de Deus School of Nursing; Horizon 2020 - Portugal 2020 (ALT20-03-0145-FEDER-000007...CompletedFallers | High Risk of FallingPortugal
-
Loma Linda UniversityCompletedBalance ChangesUnited States
-
State University of New York - Upstate Medical...CompletedMuscle Weakness
-
Philip Morris Products S.A.CompletedSmoking | Exercise CapacityGermany
-
Hull University Teaching Hospitals NHS TrustTerminated